ACC/AHA Guidelines Updated for Dyslipidemia Management

Medically reviewed by Drugs.com

via HealthDay

MONDAY, March 16, 2026 -- In a clinical practice guideline issued by the American College of Cardiology, the American Heart Association, and nine other leading medical associations, updated recommendations are presented for managing dyslipidemia. The clinical practice guideline was published online March 13 in the Journal of the American College of Cardiology and in Circulation.

Roger S. Blumenthal, M.D., from the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease in Baltimore, and colleagues updated guidelines on the management of blood cholesterol.

The authors note that to reduce lifelong risk for prolonged exposure to atherogenic lipoproteins, dyslipidemia should be treated earlier. They recommend that health behavior counseling for lifestyle optimization should start in youth; in youth with familial hypercholesterolemia and in young adults with low-density lipoprotein cholesterol (LDL-C) ≥160 mg/dL or a strong family history of premature atherosclerotic cardiovascular disease (ASCVD), pharmacotherapy should be considered early. For primary prevention in adults aged 30 to 79 years, the more contemporary American Heart Association Predicting Risk of cardiovascular disease EVENTs (PREVENT) equations should be used instead of the older Pooled Cohort Equations to guide lipid-lowering therapy (LLT). For adults with borderline ASCVD risk, LDL-lowering therapy can be considered, while it should be considered for those with intermediate risk after a clinician-patient discussion. To guide LLT, LDL-C and non-high-density lipoprotein treatment goals are recommended; once these goals are met, apolipoprotein B testing can be useful to identify those with residual elevated lipoprotein-related risk.

"While we want to try to optimize healthy lifestyle habits as the first step to lower cholesterol, we realize that if lipid numbers aren't within the desirable range after a period of lifestyle optimization, we should consider adding lipid-lowering medication earlier than we would have considered 10 years ago," Blumenthal said in a statement.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Editorial

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords